WO2001062195A1 - Antibiotic and antifungal compositions - Google Patents
Antibiotic and antifungal compositions Download PDFInfo
- Publication number
- WO2001062195A1 WO2001062195A1 PCT/US2001/005856 US0105856W WO0162195A1 WO 2001062195 A1 WO2001062195 A1 WO 2001062195A1 US 0105856 W US0105856 W US 0105856W WO 0162195 A1 WO0162195 A1 WO 0162195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibiotic
- product
- antifungal
- dosage form
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Definitions
- This invention relates to antibiotic and antifungal compositions and the use thereof. More particularly, this invention relates to a composition for the delivery of two or more antibiotics or antifungals, and the use thereof.
- the present invention is directed to a new and improved composition that delivers two or more antibiotics or two or more antifungal agents, and the use thereof.
- an antibiotic product or antifungal product for delivering at least two different antibiotics or at least two different antifungals that is comprised of at least three dosage forms each comprised of at least one antibiotic or antifungal and a pharmaceutically acceptable carrier, with one of the dosage forms including at least one of the at least two antibiotics or the at least two antifungals and at least one dosage form including at least a second antibiotic of the at least two antibiotics or at least a second antifungal of the at least two antifungals.
- each of the dosage forms may include two or more antibiotic or antifungals, or one or two of the dosage forms may include only one of the two or more antibiotic or antifungals and each of the remaining dosage forms may include only one or more of the different antibiotics or antifungals or two or more of the antibiotics or antifungals.
- an antibiotic or antifungal product for delivering at least two different antibiotic or antifungals wherein the product includes at least three dosage forms wherein each of the at least two antibiotic or antifungals is present in at least one of the three dosage forms.
- each of the dosage forms has a different release profile, with one of the dosage forms being an immediate release dosage form.
- the present invention is directed to treating a bacterial or fungal infection by administering to a host in need thereof an antibiotic or antifungal product as hereinabo ve and hereinafter described.
- a single or unitary antibiotic or antifungal product that has contained therein at least three antibiotic or antifungal dosage forms, each of which has a different release profile, whereby the antibiotic or antifungal contained in each of the at least three dosage forms is released at different times, and wherein at least one of the dosage forms includes at least a first antibiotic or antifungal and at least one of the dosage forms includes at least a second antibiotic or antifungal different from the first antibiotic or antifungal.
- the antibiotic or antifungal product may be comprised of at least four different dosage forms, each of which starts to release the antibiotic or antifungal contained therein at different times after administration of the antibiotic or antifungal product.
- the antibiotic or antifungal product generally does not include more than five dosage forms with different release times.
- the antibiotic or antifungal product has an overall release profile such that when administered the maximum serum concentration of the total antibiotic or antifungal released from the product is reached in less than twelve hours, preferably in less than eleven hours. In an embodiment, the maximum serum concentration of the total antibiotic or antifungal released from the antibiotic or antifungal product is achieved no earlier than four hours after administration.
- one of the at least three dosage forms is an immediate release dosage form whereby initiation of release of antibiotic or antifungal therefrom is not substantially delayed after administration of the antibiotic or antifungal product.
- the second and third of the at least three dosage forms is a delayed dosage form (which may be a pH sensitive or a non-pH sensitive delayed dosage form, depending on the type of antibiotic or antifungal product), whereby antibiotic or antifungal released therefrom is delayed until after initiation of release of antibiotic or antifungal from the immediate release dosage form.
- antibiotic or antifungal release from the second of the at least two dosage forms achieves a C raax (maximum serum concentration in the serum) at a time after antibiotic or antifungal released from the first of the at least three dosage forms achieves a C max in fhe serum, and antibiotic or antifungal released from the third dosage form achieves a C max in the serum after the C max of antibiotic or antifungal released from the second dosage form.
- C raax maximum serum concentration in the serum
- the second of the at least two dosage forms initiates release of antibiotic or antifungal contained therein at least one hour after the first dosage form, with the initiation of the release therefrom generally occurring no more than six hours after initiation of release of antibiotic or antifungal from the first dosage form of the at least three dosage forms.
- the immediate release dosage form produces a C max for antibiotic or antifungal released therefrom within from about 0.5 to about 2 hours, with the second dosage form of fhe at least three dosage forms producing a C ma for antibiotic or antifungal released therefrom in no more than about four hours.
- the Cmax for such second dosage form is achieved no earlier than two hours after administration of the antibiotic or antifungal product; however, it is possible within the scope of the invention to achieve C max in a shorter period of time.
- the antibiotic or antifungal product may contain at least three or at least four or more different dosage forms.
- the antibiotic or antifungal released from the third dosage form reaches a C ma ⁇ at a time later than the C max is achieved for antibiotic or antifungal released from each of the first and second dosage forms.
- release of antibiotic or antifungal from fhe third dosage form is started after initiation of release of antibiotic or antifungal from both the first dosage form and the second dosage form.
- C max for antibiotic or antifungal release from the third dosage form is achieved within eight hours.
- the antibiotic or antifungal product contains at least four dosage forms, with each of the at least four dosage forms having different release profiles, whereby antibiotic or antifungal released from each of the at least four different dosage forms achieves a C max at a different time.
- C ma ⁇ for all the antibiotic or antifungal released from the antibiotic or antifungal product is achieved in less than twelve hours, and more generally is achieved in less than eleven hours.
- the antibiotic or antifungal product is a once a day product, whereby after administration of the antibiotic or antifungal product, no further product is administered during the day; i.e., the preferred regimen is that the product is administered only once over a twenty-four hour period.
- the preferred regimen is that the product is administered only once over a twenty-four hour period.
- a single dosage antibiotic or antifungal product comprised of at least three antibiotic or antifungal dosage forms each having a different release profile with each of the dosage forms including at least one of a first or second antibiotic or antifungal and at least one of fhe three dosage forms including at least the first antibiotic or antifungal and at least one of the dosage forms including at least the second antibiotic or antifungal.
- Each of the dosage forms of antibiotic or antifungal in a pharmaceutically acceptable carrier may have one or more antibiotic or antifungals.
- the fourth of the at least four dosage form may be a sustained release dosage form or a delayed release dosage form. If the fourth dosage form is a sustained release dosage form, even though C max of the fourth dosage form of the at least four dosage forms is reached after the C max of each of the other dosage forms is reached, antibiotic or antifungal release from such fourth dosage form may be initiated prior to or after release from the second or third dosage form.
- an antibiotic or antifungal composition that is a mixture of antibiotic or antifungal compositions or dosage forms wherein said composition contains a first composition or dosage form comprising a first antibiotic or antifungal and a pharmaceutically acceptable carrier; a second composition or dosage form comprising the first antibiotic or antifungal and a pharmaceutically acceptable carrier; a third composition or dosage form comprising a second antibiotic or antifungal different from the first antibiotic or antifungal and a pharmaceutically acceptable carrier; and a fourth composition or dosage form comprising fhe second antibiotic or antifungal and a pharmaceutically acceptable carrier; wherein the second and third compositions each .have a release profile that provides a maximum serum concentration of the first antibiotic or antifungal released from the second composition and a maximum serum concentration for the second antibiotic or antifungal released from fhe third composition at a time after the first antibiotic or antifungal released from the first composition reaches a maximum serum concentration, and wherein the fourth composition has a release profile that provides for a maximum serum concentration of the
- the release profiles of the second and third composition are such that the maximum serum concentration of the first antibiotic or antifungal released from fhe second composition, and the maximum serum concentration of the second antibiotic or antifungal released from the third composition are reached at approximately the same time, or where the first antibiotic or antifungal reaches a maximum serum concentration before or after the second antibiotic or antifungal reaches a maximum serum concentration.
- a first pulse in which a first antibiotic or antifungal reaches a maximum serum concentration
- a second pulse wherein a further dosage of the first antibiotic or antifungal, and an initial dosage of the second antibiotic or antifungal reach a maximum serum concentration at a time after fhe first pulse of fhe first antibiotic or antifungal reaches a maximum serum concentration
- a third pulse wherein an additional dosage of fhe second antibiotic or antifungal reaches a maximum serum concentration at a time after fhe maximum serum concentration is reached for each of the first and second antibiotic or antifungal dosages provided in the second pulse.
- first dosage of the first antibiotic or antifungal achieves a maximum serum concentration within four hours after administration of the antibiotic or antifungal composition; the second dosage of the first antibiotic or antifungal and the first dosage of the second antibiotic or antifungal each reach a maximum serum concentration within four to eight hours after administration of the antibiotic or antifungal composition; and the second dosage of the second antibiotic or antifungal reaches a maximum serum concentration within twelve hours after administration of the antibiotic or antifungal composition.
- an antibiotic or antifungal composition that includes four different dosage forms, with the first dosage form providing an initial dosage of a first antibiotic or antifungal, the second dosage form providing a further dosage of the first antibiotic or antifungal; the third dosage form providing an initial dosage of a second antibiotic or antifungal; and the fourth dosage form providing an additional dosage of the second antibiotic or antifungal, wherein the antibiotic or antifungals released from the second and third dosage forms reach a maximum serum concentration at a time after the antibiotic or antifungal released from the first dosage form reaches a maximum serum concentration, and the antibiotic or antifungal released from fhe fourth dosage form reaching a maximum serum concentration at a time after fhe times at which the antibiotic or antifungals released from each of the first, second, and third dosage forms reach a maximum serum concentration.
- the first dosage form provides for immediate release
- the second and third dosage forms provide for a delayed release (pH or non pH dependent, with the second dosage form preferably being a pH dependent release)
- the fourth dosage form provides for pH dependent or non pH dependent release preferably non pH dependent release.
- the first dosage form generally contains from about 30 percent to about 80 percent of the first antibiotic or antifungal; the second dosage form contains from about 30 percent to about 80 percent of the first antibiotic or antifungal; the third dosage form contains from about 30 percent to about 80 percent of the second antibiotic or antifungal, and the fourth antibiotic or antifungal dosage form contains from about 30 percent to about 80 percent of the second antibiotic or antifungal.
- each unit or dosage form is present in an amount of at least 20 percent by weight, with each dosage form or unit being present in the overall composition in an amount that generally does not exceed 60 percent by weight.
- Each of the first and second dosage forms include from 20% to 80% of the total dosage of the first antibiotic or antifungal to be provided by the composition, and each of the first and second dosage forms may include the same or different dosages of the first antibiotic or antifungal.
- Each of the third and fourth dosage forms include from 20% to 80% of the total dosage of the second antibiotic or antifungal to be delivered by the composition, and each of the third and fourth units may have the same or different dosages of fhe antibiotic or antifungal.
- the immediate release dosage form of the product generally provides from about 20% to about 50% of the total dosage of antibiotic or antifungal to be delivered by the product, with such immediate release dosage form generally providing at least 25% of the total dosage of the antibiotic or antifungal to be delivered by the product.
- the immediate release dosage form provides from about 20% to about 30% of the total dosage of antibiotic or antifungal to be delivered by the product; however, in some cases it may be desirable to have the immediate release dosage form provide for about 45% to about 50% of fhe total dosage of antibiotic or antifungal to be delivered by fhe product.
- each of the delayed release dosage forms may provide about equal amounts of antibiotic or antifungal; however, they may also be formulated so as to provide different amounts.
- the immediate release component provides from 20% to 35% (preferably 20% to 30%), by weight, of fhe total antibiotic or antifungal; where there is three delayed release components, the immediate release component provides from 15% to 30%, by weight, of the total antibiotic or antifungal; and where there are four delayed release components, fhe immediate release component provides from 10% to 25%, by weight, of the total antibiotic or antifungal.
- the first delayed release component (the one released earlier in time) provides from 30% to 60%, by weight, of the total antibiotic or antifungal provided by the two delayed release components with the second delayed release component providing the remainder of fhe antibiotic or antifungal.
- fhe earliest released component provides 20% to 35% by weight of fhe total antibiotic or antifungal provided by the three delayed release components
- the next in time delayed release component provides from 20% to 40%, by weight, of the antibiotic or antifungal provided by the three delayed release components and the last in time providing the remainder of the antibiotic or antifungal provided by the three delayed release components.
- the earliest delayed release component provides from 15% to 30%, by weight
- the next in time delayed release component provides from 15% to 30%
- fhe next in time delayed release component provides from 20% to 35%, by weight
- the last in time delayed release component provides from 20% to 35%, by weight, in each case of the total antibiotic or antifungal provided b the four delayed release components.
- the overall composition includes each of the antibiotic or antifungals in a therapeutically effective amount.
- the specific amount(s) is dependant on the antibiotic or antifungal used, the disease or infection to be treated, and the number of times of day that fhe composition is to be administered.
- the antibiotic or antifungal composition of the present invention may be administered for example, by any one of the following routes of administration: sublingual, fransmucosal, transdermal, parenteral, oral, preferably by oral administration.
- the antibiotic or antifungal product of the present invention may be formulated for administration by a variety of routes of administration.
- the antibiotic or antifungal product may be formulated in a way that is suitable for topical administration; administration in the eye or the ear; rectal or vaginal administration; as nose drops; by inhalation; as an injectable; or for oral administration.
- the antibiotic or antifungal product is formulated in a manner such that it is suitable for oral administration.
- the at least two different dosage forms may be formulated for topical administration by including such dosage forms in an oil-in-water emulsion, or a water-in-oil emulsion.
- the immediate release dosage form is in the continuous phase
- the delayed release dosage form is in a discontinuous phase.
- the formulation may also be produced in a manner for delivery of three dosage forms as hereinabove described.
- an oil- in-water-in-oil emulsion with oil being a continuous phase that contains the immediate release component, water dispersed in fhe oil containing a first delayed release dosage form, and oil dispersed in the water containing a third delayed release dosage form.
- an antibiotic or antifungal product in the form of a patch, which includes antibiotic or antifungal dosage forms having different release profiles, as hereinabove described.
- fhe antibiotic or antifungal product may be formulated for use in the eye or ear or nose, for example, as a liquid emulsion.
- the dosage form may be coated with a hydrophobic polymer whereby a dosage form is in the oil phase of the emulsion, and a dosage form may be coated with hydrophilic polymer, whereby a dosage form is in the water phase of the emulsion.
- the antibiotic or antifungal product with at least three different dosage forms with different release profiles may be formulated for rectal or vaginal administration, as known in the art. This may take the form of a cream or emulsion, or other dissolvable dosage form similar to those used for topical administration.
- the antibiotic or antifungal product may be formulated for use in inhalation therapy by coating the particles and micronizing the particles for inhalation.
- the antibiotic or antifungal product is formulated in a manner suitable for oral administration.
- each of the dosage forms may be used as a pellet or a particle, with a pellet or particle then being formed into a unitary pharmaceutical product, for example, in a capsule, or embedded in a tablet, or suspended in a liquid for oral administration.
- each of the dosage forms of the product may be formulated as a tablet, with each of the tablets being put into a capsule to produce a unitary antibiotic or antifungal product.
- antibiotic or antifungal products may include a first dosage form in the form of a tablet that is an immediate release tablet, and may also include two or more additional tablets, each of which provides for a delayed release of the antibiotic or antifungal, as hereinabove described;, whereby fhe C max of the antibiotic or antifungal released from each of the tablets is reached at different times, with the C max of the total antibiotic or antifungal released from the antibiotic or antifungal product being achieved in less than twelve hours.
- an antibiotic or antifungal product including at least three dosage forms with different release profiles for different routes of administration is deemed to be within the skill of the art from the teachings herein.
- the time of release can be controlled by the concentration of antibiotic or antifungals in fhe coating and/or the thickness of the coating.
- the first and second antibiotic employed in fhe antibiotic composition may be a wide variety of products.
- fhe combination of first and second antibiotics that are used in the composition may be, for example, a penicillin and an aminoglycoside, such as gentamycin, tobramicin, amikacin or vancomycin.
- Another antibiotic that may be employed is a combination of a sulfonamide, such as sulfamefhoxasol, which would be combined with trimethoporim.
- amphotericin B flucytosine, fluconazole, griseofulvin, miconazole nitrate, terbinafine hydrochloride, ketoconazole, itraconazole, undecylenic acid and chloroxylenol, ciclopirox, clotrimazole, butenafme hydrochloride, nystatin, naftifine hydrochloride, oxiconazole nitrate, selenium sulf ⁇ de, econazole nitrate, terconazole, butoconazole nitrate, carbol-fuchsin, clioquinol, methylrosaniline chloride, sodium hiosulfate, sulconazole nitrate, terbinafine hydrochloride, tioconazole, tolnaftate, undecylenic acid and undecylenate salts (
- each of the first and second antibiotic or first and second antifungal is each from a different class of antibiotic or antifungal.
- the immediate release portion of this system can be a mixture of ingredients that breaks down quickly after administration to release fhe antibiotic or antifungal. This can take the form of either a discrete pellet or granule that is mixed in with, or compressed with, the other three components.
- the materials to be added to fhe antibiotic or antifungals for fhe immediate release component can be, but are not limited to, microcrystalline cellulose, corn starch, pregelatinized starch, potato starch, rice starch, sodium carboxymethyl starch, hydroxypropylcellulose, ydroxypropylmethylcellulose, hydroxye hylcellulose, efhylcellulose, chitosan, hydroxychitosan, hydroxymethylatedchitosan, cross-linked chitosan, cross-linked hydroxyme hyl chitosan, maltodextrin, mannitol, sorbitol, dextrose, maltose, fructose, glucose, levulose, sucrose, polyvinylpyrrolidone (PVP), acrylic acid derivatives (Carbopol, Eudragit, etc.), polyethylene glycols, such a low molecular weight PEGs (PEG2000- 10000) and high molecular weight PEGs (Poly
- ingredients in this system may be useful to have other ingredients in this system to aid in the dissolution of the drug, or the breakdown of fhe component after ingestion or administration.
- These ingredients can be surfactants, such as sodium lauryl sulfate, sodium monoglycerate, sorbitan monooleate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, glyceryl monostearate, glyceryl monooleate, glyceryl monobutyrate, one of the non-ionic surfactants such as the Pluronic line of surfactants, or any other material with surface active properties, or any combination of the above.
- WAV 0.05-15%
- compositions in this composition are the same immediate release unit, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- Materials that can be used to obtain a delay in release suitable for this component of the invention can be, but are not limited to, polyethylene glycol (PEG) with molecular weight above 4,000 daltons (Carbowax, Polyox), waxes such as white wax or bees wax, paraffin, acrylic acid derivatives (Eudragit), propylene glycol, and ethylcellulose.
- PEG polyethylene glycol
- Carbowax, Polyox polyethylene glycol
- waxes such as white wax or bees wax
- paraffin acrylic acid derivatives
- acrylic acid derivatives Eudragit
- propylene glycol and ethylcellulose
- these materials can be present in the range of 0.5-25% (WAV) of this component.
- compositions in this composition are the same as the immediate release component, but with additional polymers integrated into fhe composition, or as coatings over the pellet or granule.
- the kind of materials useful for this purpose can be, but are not limited to, cellulose acetate pthalate, Eudragit L, and other p halate salts of cellulose derivatives.
- Formulate the composition by mixing the ingredients in a suitable pharmaceutical mixer or granulator such as a planetary mixer, high-shear granulator, fluid bed granulator, or extruder, in the presence of water or other solvent, or in a dry blend. If water or other solvent was used, dry the blend in a suitable pharmaceutical drier, such as a vacuum oven or forced-air oven.
- a suitable pharmaceutical drier such as a vacuum oven or forced-air oven.
- the product may be sieved or granulated, and compressed using a suitable tablet press, such as a rotary tablet press.
- Polyethylene glycol 4000 Polyethylene glycol 2000 10 Hydroxypropylcellulose 5
- Clarithromycin 65% (WAV) Microcrystalline cellulose 20 Hydroxypropylcellulose 10 Croscarmellose sodium 5
- Clarithromycin 75% Microcrystalline cellulose 15 Hydroxypropylcellulose 5 Croscarmellose sodium 5
- Clarithromycin 75% (WAV) Polyethylene glycol 8000 20 Polyvinylpyrrolidone 5
- Ciprofoxacin 75% Microcrystalline cellulose 15 Hydroxypropylcellulose 5 Croscarmellose sodium 5
- Ciprofoxacin 75% (WAV) Polyethylene glycol 4000 10 Poly heylene glycol 2000 10 Hydroxypropylcellulose 5
- Polyethylene glycol 4000 Polyethylene glycol 2000 10 Hydroxypropylcellulose 5
- Polyethylene glycol 4000 Polyethylene glycol 2000 10 Hydroxypropylcellulose 5
- Ketoconazole 65% (WAV) Microcrystalline cellulose 20 Hydroxypropylcellulose 10 Croscarmellose sodium 5
- Example 22
- Ketoconazole 75% Microcrystalline cellulose 15 Hydroxypropylcellulose 5 Croscarmellose sodium 5
- Ketoconazole 75% (WAV) Polyethylene glycol 4000 10 Polyethylene glycol 2000 10 Hydroxypropylcellulose 5
- Ketoconazole 75% (WAV) Polyethylene glycol 8000 20 Polyvinylpyrrolidone 5
- Polyethylene glycol 4000 Polytheylene glycol 2000 10 Hydroxypropylcellulose 5
- Cirpofloxacin 75% Polyethylene glycol 8000 20 Polyvinylpyrrolidone 5
- Formulate the composition by mixing the ingredients in a suitable pharmaceutical mixer or granulator such as a planetary mixer, high-shear granulator, fluid bed granulator, or extruder, in the presence of water or other solvent, or in a hot melt process. If water or other solvent was used, dry the blend in a suitable pharmaceutical drier, such as a vacuum oven or forced-air oven. Allow the product to cool, the product may be sieved or granulated, and compressed using a suitable tablet press, such as a rotary tablet press.
- a suitable pharmaceutical mixer or granulator such as a planetary mixer, high-shear granulator, fluid bed granulator, or extruder
- a suitable pharmaceutical drier such as a vacuum oven or forced-air oven. Allow the product to cool, the product may be sieved or granulated, and compressed using a suitable tablet press, such as a rotary tablet press.
- Clarithromycin 80% (WAV) Polyethylene glycol 8000 10 Polyvinylpyrrolidone 5 Eudgragit R 30D 5
- Ciprofoxacin 65% (WAV) Polyethylene glycol 4000 20 Hydroxypropylcellulose 10 Eudragit RL 30D 5
- Ciprofoxacin 75% (WAV) Microcrystalline cellulose 15 Hydroxypropylcellulose 5 Ethylcellulose 5
- Ciprofoxacin 75% (WAV) Polyethylene glycol 8000 20 Ethylcellulose 5
- Ketoconazole 75% (WAV) Polyethylene glycol 4000 10 Polyethylene glycol 2000 10 Eudragit RL 30D 5
- Ketoconazole 80% (WAV) Polyethylene glycol 8000 10 Polyvinylpyrrolidone 5 Eudgragit R 30D 5
- Polyethylene glycol 4000 10 Polyethylene glycol 2000 5 Eudgragit RL 30D 5
- Formulate the ingredients by mixing the ingredients in a suitable pharmaceutical mixer or granulator such as a planetary mixer, high-shear granulator, fluid bed granulator, or extruder, in the presence of water or other solvent, or in a hot melt process. If water or other solvent was used, dry the blend in a suitable pharmaceutical drier, such as a, vacuum oven or forced-air oven. Allow the product to cool, the product may be sieved or granulated, and compressed using a suitable tablet press, such as a rotary tablet press.
- a suitable pharmaceutical mixer or granulator such as a planetary mixer, high-shear granulator, fluid bed granulator, or extruder
- a suitable pharmaceutical drier such as a, vacuum oven or forced-air oven. Allow the product to cool, the product may be sieved or granulated, and compressed using a suitable tablet press, such as a rotary tablet press.
- Ciprofoxacin 70% (WAV) Polyethylene glycol 4000 20 Cellulose acetate pthalate 10
- Microcrystalline cellulose 20 Cellulose acetate pthalate 10
- Microcrystalline cellulose 20 Cellulose Acetate Pthalate 15
- Ketoconazole 75% (WAV) Polyethylene glycol 2000 10 Eudragit L 30D 15
- composition of the antibiotic matrix pellets provided in Table 1.
- composition of the aqueous Eudragit L30D-55 dispersion applied to the antibiotic matrix pellets is provided below in Table 2.
- the TEC/talc suspension is then homogenized using a PowerGen 700 high shear mixer.
- composition of the aqueous Eudragit® S 100 dispersion applied to the antibiotic matrix pellets is provided below in Table 3.
- Part B is then added slowly to the polymer dispersion in Part A with a mild stirring.
- Pellets are filled into size 00 hard gelatin capsules at a ratio of 30%: 30%: 40%: Immediate-release matrix pellets uncoated, L30 D-55 coated pellets and SI 00 coated pellets respectively.
- the capsule is filled with fhe three different pellets to achieve a the desire dosage.
- the immediate release matrix pellets include the first antibiotic, the L30 D-55 coated pellets are made by coating matrix pellets that contain the second antibiotic and the SI 00 coated pellets are made by coating matrix pellets that contain the first antibiotic.
- composition of the Antibiotictrihydrate matrix pellets provided in Table 4.
- composition of the aqueous Eudragit L30D-55 dispersion applied to fhe Antibioticmatrix pellets is provided below in Table 5.
- the TEC/talc suspension is mixed using laboratory mixer.
- composition of fhe aqueous Eudragit® S 100 dispersion applied to fhe Antibioticmatrix pellets is provided below in Table 6.
- Part A Part A:
- Part B is then added slowly to the polymer dispersion in Part A with a mild stirring.
- Spray nozzle diameter 1.0 mm Material Charge 300 gram Inlet Air Temperature 40 to 45 °C Outlet Air Temperature 30 to 33 °C
- composition of the antibiotic matrix pellets provided in Table 9.
- composition of fhe aqueous Eudragit L30D-55 dispersion applied to the antibiotic matrix pellets is provided below in Table 10.
- the TEC/talc suspension is then homogenized using a PowerGen 700 high shear mixer.
- composition of the aqueous Eudragit® S 100 dispersion applied to the antibiotic matrix pellets is provided below in Table 11.
- PartB 104.6.5 Disperse talc in the required amount of water 104.6.6 Homogenize the dispersion using a PowerGen 700D high shear mixer.
- Part B is then added slowly to the polymer dispersion in Part A with a mild stirring.
- Pellets are filled into size 00 hard gelatin capsules at a ratio of 20%: 30%: 20%: 30% Immediate-release matrix pellets (uncoated), L30 D-55 coated pellets 12% weight gain, L30D-55 coated pellets 30% weight gain and SI 00 coated pellets respectively.
- the capsule is filled with the four different pellets to achieve the desired dosage.
- the immediate release pellets contain fhe first antibiotic; the L30 D-55 12% weight gain coated pellets contain the second antibiotic; the L30 D-55 30% weight gain coated pellets contain the first antibiotic and the SI 00 coated pellets contain the second antibiotic.
- Examples 102-104 may be used to produce an antifungal product that contains two different antifungal agents.
- the present invention is advantageous in that a sy ⁇ ergistic antibiotic or antifungal will be dosed in an alternate pulse to another, synergistic antibiotic or antifungal. This will alternate the exposure to fhe bacteria in such a way as to make both antibiotics or antifungals more effective than if they were co-administered, and thereby competing with each other for sites on the bacterial or fungal cell wall receptors, or sites within the bacterial or fungal cells.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002400818A CA2400818C (en) | 2000-02-24 | 2001-02-23 | Antibiotic and antifungal compositions |
EP01914454A EP1267765A4 (en) | 2000-02-24 | 2001-02-23 | Antibiotic and antifungal compositions |
AU2001239841A AU2001239841B2 (en) | 2000-02-24 | 2001-02-23 | Antibiotic and antifungal compositions |
JP2001561265A JP2003523372A (en) | 2000-02-24 | 2001-02-23 | Antibiotics and antifungal compositions |
AU3984101A AU3984101A (en) | 2000-02-24 | 2001-02-23 | Antibiotic and antifungal compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18454500P | 2000-02-24 | 2000-02-24 | |
US60/184,545 | 2000-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001062195A1 true WO2001062195A1 (en) | 2001-08-30 |
Family
ID=22677345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/005856 WO2001062195A1 (en) | 2000-02-24 | 2001-02-23 | Antibiotic and antifungal compositions |
Country Status (6)
Country | Link |
---|---|
US (1) | US6623757B2 (en) |
EP (1) | EP1267765A4 (en) |
JP (1) | JP2003523372A (en) |
AU (2) | AU2001239841B2 (en) |
CA (1) | CA2400818C (en) |
WO (1) | WO2001062195A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024174A2 (en) * | 2000-09-22 | 2002-03-28 | Galephar M/F | Sustained release composition containing clarithromycin |
WO2003105903A1 (en) * | 2002-06-18 | 2003-12-24 | ポーラ化成工業株式会社 | Antifungal medicinal composition |
EP1487414A2 (en) * | 2002-03-07 | 2004-12-22 | Advancis Pharmaceutical Corporation | Antibiotic composition |
JP2006528699A (en) * | 2003-05-19 | 2006-12-21 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic composition |
US8303988B2 (en) | 2000-10-13 | 2012-11-06 | Shionogi Inc. | Antifungal once-a-day product, use and formulation thereof |
US8889187B2 (en) | 2000-02-24 | 2014-11-18 | Shionogi Inc. | Once a day amoxicillin product comprising immediate and delayed release dosage forms |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US6623757B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Antibiotic composition |
US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
EP1330236A2 (en) | 2000-10-12 | 2003-07-30 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
US20020197314A1 (en) | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
US7119062B1 (en) | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
US20040115261A1 (en) * | 2001-04-05 | 2004-06-17 | Ashley Robert A. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
EP2204168B1 (en) | 2003-04-07 | 2015-01-14 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
JP2006528185A (en) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
EP1648407A4 (en) | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
JP2006528189A (en) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic products, their use and formulation |
US8758820B2 (en) | 2003-08-11 | 2014-06-24 | Shionogi Inc. | Robust pellet |
EP1653924A4 (en) * | 2003-08-12 | 2009-09-09 | Middlebrook Pharmaceuticals In | Antibiotic product, use and formulation thereof |
AU2004270170B2 (en) * | 2003-08-29 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
US8460710B2 (en) | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
SI21637A (en) * | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Pharmaceutical form with controlled release |
WO2005062898A2 (en) * | 2003-12-24 | 2005-07-14 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
WO2006014427A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
US20060240108A1 (en) * | 2005-04-26 | 2006-10-26 | Bernard Bobby L | Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability |
CA2606386C (en) * | 2005-04-29 | 2014-06-10 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
US8357394B2 (en) * | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US20080139526A1 (en) * | 2006-12-06 | 2008-06-12 | Donald Treacy | Modified release dosage forms of amoxicillin |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
SG11201914046WA (en) | 2017-07-07 | 2020-01-30 | Epicentrx Inc | Compositions for parenteral administration of therapeutic agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5414014A (en) * | 1993-04-08 | 1995-05-09 | Innova Biomed, Inc. | Methods for efficacious removal of attached, sucking antropods from human dermis |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL64009A (en) * | 1980-10-31 | 1984-09-30 | Rech Applications Therap | Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them |
US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
JPS601128A (en) * | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | Long-acting cefaclor preparation |
US4616008A (en) * | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
JPS61210025A (en) * | 1985-03-14 | 1986-09-18 | Teisan Seiyaku Kk | Stabilized antibioitc complex granule preparation |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4782059A (en) * | 1986-09-29 | 1988-11-01 | Merck & Co., Inc. | Method of controlling mycotic infections and compositions therefor |
JPS63162619A (en) * | 1986-12-25 | 1988-07-06 | Teisan Seiyaku Kk | Delayed soluble granule and sustained release complex granule using said granule |
US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US5110597A (en) | 1987-06-25 | 1992-05-05 | Alza Corporation | Multi-unit delivery system |
US4915953A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering acetaminophen or phenylpropanolamine |
US4971805A (en) | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
DK469989D0 (en) | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
IT1255522B (en) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
IL109770A0 (en) | 1993-05-29 | 1994-11-28 | Smithkline Beecham Corp | Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby |
AU7966694A (en) * | 1993-07-21 | 1996-05-02 | University Of Kentucky Research Foundation, The | A multicompartment hard capsule with control release properties |
GB9402203D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
HU215443B (en) * | 1994-07-25 | 1999-04-28 | Márton Milánkovits | Pharmaceutical compositions, first of all vaginal suppositorium, containing more active components with bactericide, fungicide, antiprotozoonic and antiviral combined activity |
GB9416600D0 (en) | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5827531A (en) | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
SE9600072D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
IL119627A (en) | 1996-11-17 | 2002-03-10 | Yissum Res Dev Co | PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT |
IT1289160B1 (en) | 1997-01-08 | 1998-09-29 | Jagotec Ag | FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
DE19718012C1 (en) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Process for the production of orally applicable solid pharmaceutical forms with controlled release of active substances |
US5877243A (en) * | 1997-05-05 | 1999-03-02 | Icet, Inc. | Encrustation and bacterial resistant coatings for medical applications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
AUPP437698A0 (en) * | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US20020004070A1 (en) | 2000-02-24 | 2002-01-10 | Rudnic Edward M. | Antineoplastic product, use and formulation thereof |
US6623757B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Antibiotic composition |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
-
2001
- 2001-02-23 US US09/791,983 patent/US6623757B2/en not_active Expired - Lifetime
- 2001-02-23 AU AU2001239841A patent/AU2001239841B2/en not_active Expired
- 2001-02-23 AU AU3984101A patent/AU3984101A/en active Pending
- 2001-02-23 WO PCT/US2001/005856 patent/WO2001062195A1/en active Application Filing
- 2001-02-23 EP EP01914454A patent/EP1267765A4/en not_active Withdrawn
- 2001-02-23 CA CA002400818A patent/CA2400818C/en not_active Expired - Fee Related
- 2001-02-23 JP JP2001561265A patent/JP2003523372A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5414014A (en) * | 1993-04-08 | 1995-05-09 | Innova Biomed, Inc. | Methods for efficacious removal of attached, sucking antropods from human dermis |
Non-Patent Citations (1)
Title |
---|
See also references of EP1267765A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889187B2 (en) | 2000-02-24 | 2014-11-18 | Shionogi Inc. | Once a day amoxicillin product comprising immediate and delayed release dosage forms |
WO2002024174A2 (en) * | 2000-09-22 | 2002-03-28 | Galephar M/F | Sustained release composition containing clarithromycin |
WO2002024174A3 (en) * | 2000-09-22 | 2002-09-26 | Galephar M F | Sustained release composition containing clarithromycin |
US8303988B2 (en) | 2000-10-13 | 2012-11-06 | Shionogi Inc. | Antifungal once-a-day product, use and formulation thereof |
EP1487414A2 (en) * | 2002-03-07 | 2004-12-22 | Advancis Pharmaceutical Corporation | Antibiotic composition |
JP2005526059A (en) * | 2002-03-07 | 2005-09-02 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic composition |
EP1487414A4 (en) * | 2002-03-07 | 2007-12-12 | Advancis Pharmaceutical Corp | Antibiotic composition |
WO2003105903A1 (en) * | 2002-06-18 | 2003-12-24 | ポーラ化成工業株式会社 | Antifungal medicinal composition |
JP2006528699A (en) * | 2003-05-19 | 2006-12-21 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic composition |
Also Published As
Publication number | Publication date |
---|---|
CA2400818A1 (en) | 2001-08-30 |
JP2003523372A (en) | 2003-08-05 |
EP1267765A1 (en) | 2003-01-02 |
AU2001239841B2 (en) | 2006-04-27 |
US20020004499A1 (en) | 2002-01-10 |
EP1267765A4 (en) | 2008-12-24 |
CA2400818C (en) | 2009-01-06 |
US6623757B2 (en) | 2003-09-23 |
AU3984101A (en) | 2001-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2400818C (en) | Antibiotic and antifungal compositions | |
US8303988B2 (en) | Antifungal once-a-day product, use and formulation thereof | |
AU2001239841A1 (en) | Antibiotic and antifungal compositions | |
US20050238714A1 (en) | Anti-fungal composition | |
US6610328B2 (en) | Amoxicillin-clarithromycin antibiotic composition | |
US6638532B2 (en) | Tetracycline—doxycycline antibiotic composition | |
US6991807B2 (en) | Antibiotic composition | |
US8889187B2 (en) | Once a day amoxicillin product comprising immediate and delayed release dosage forms | |
US6730320B2 (en) | Tetracycline antibiotic product, use and formulation thereof | |
US6541014B2 (en) | Antiviral product, use and formulation thereof | |
US6627222B2 (en) | Amoxicillin-dicloxacillin antibiotic composition | |
US6623758B2 (en) | Cephalosporin-metronidazole antibiotic composition | |
US6663891B2 (en) | Erythromyacin antibiotic product, use and formulation thereof | |
US6632453B2 (en) | Ciprofoxacin-metronidazole antibiotic composition | |
US6667042B2 (en) | Fluroquinilone antibiotic product, use and formulation thereof | |
US7157095B2 (en) | Multiple-delayed release antifungal product, use and formulation thereof | |
CA2470016A1 (en) | Antibiotic product, use and formulation thereof | |
CA2478121A1 (en) | Antibiotic composition | |
AU2003218024C1 (en) | Antibiotic composition | |
AU2006201923A1 (en) | Therapeutic product, use and formulation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2400818 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001914454 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 561265 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001239841 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001914454 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |